
Litifilimab Shows Sustained Skin Responses at 52 Weeks in Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPMmJYNWlkX09PUjNrUG5KblZOMGdWb2VzTUZoWUR4TUVVUHc5YUFBTENKYXdHYWZzYXZ5NXh5ZGdFZGplX0l6NkhTVVljeXNSRkhwQldCaGx1Ry1rYlplVEpsM0VHM0duUk8yTFRTLVBhRUhpS2NVR1ktNjdEY2ZvVmliX1BTMjFFYUk4SHJZR0tTTkY1U1NUWg?oc=5" target="_blank">Litifilimab Shows Sustained Skin Responses at 52 Weeks in Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus</a>&nbsp;&nbsp;<font color="#6f6f6f">BioPharm International</font>

